Astepro Nasal Antihistamine Spray Is Approved to Be Sold Without a Prescription

Allergies & Asthma

The Asthma and Allergy Foundation of America (AAFA) is sharing this press release from the Food and Drug Administration (FDA) to bring you the latest news quickly.


[PRESS RELEASE]

Approval is a First-in-class and was Enabled by the Prescription to Nonprescription Switch Process

For Immediate Release: June 17, 2021 – The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch. The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis—commonly known as allergies—for adults and children six years of age and older.

“Seasonal and perennial allergies affect millions of Americans every year, causing them to experience symptoms of nasal congestion, runny nose, sneezing and more,” said Theresa M. Michele, M.D., director of the office of nonprescription drugs in the FDA’s Center for Drug Evaluation and Research. “Today’s approval provides individuals an option for a safe and effective nasal antihistamine without requiring the assistance of a healthcare provider.”

For a drug to switch from prescription to nonprescription status, the data provided must demonstrate that the drug is safe and effective for use in self-medication as directed in proposed labeling. The manufacturer must show that consumers can understand how to use the drug safely and effectively without the supervision of a healthcare professional. This approval is a first-in-class switch for a nasal antihistamine and is considered a partial switch because the 0.1% strength, which includes the perennial allergy indication for children 6 months to 6 years old and seasonal allergy indication for children 2 to 6 years old, will remain prescription based.

Azelastine can cause drowsiness. The label warns that consumers using this product should avoid alcoholic drinks and be careful when driving a motor vehicle or operating machinery. Using azelastine nasal spray with alcohol, sedatives, or tranquilizers may increase drowsiness.

The FDA granted the approval of nonprescription Astepro to Bayer Healthcare LLC.

Inquiries

Media:
Courtney Rhodes
202-281-5237

Consumer:
888-INFO-FDA

Products You May Like

Articles You May Like

Positive future orientation and strong parental support linked with lower risk of youth vaping
CancerLand Bookshelf : Loosen
10 things to do this August
At 13 Years Old, Momiji Nishiya Wins Gold in Women’s Olympic Street Skateboarding
Learn How to Manage Nasal Polyps (Live Online Event)

Leave a Reply

Your email address will not be published. Required fields are marked *